ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to cancer; and Sleeping Beauty (SB), which is based on the genetic engineering of T-cells using the (SB) system to rapidly reprogram T-cells outside of the body for infusion. Its lead gene therapy product candidate is Ad-RTS-hIL-12 plus veledimex, which is in Phase I clinical trial, a gene therapy product candidate to treat patients with recurrent glioblastoma. The company is also developing chimeric antigen receptor (CAR) T-cell and T-cell receptor T-cell therapies. ZIOPHARM Oncology, Inc. has collaboration agreements with Precigen, Inc., MD Anderson Cancer Center, the National Cancer Institute, and Ares Trading S.A. The company is headquartered in Boston, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:ZIOP
CUSIP98973P10
Phone617-259-1970
Debt
Debt-to-Equity RatioN/A
Current Ratio7.17
Quick Ratio7.17
Price-To-Earnings
Trailing P/E Ratio-6.32
Forward P/E Ratio-6.33
P/E GrowthN/A
Sales & Book Value
Annual Sales$6.39 million
Price / Sales73.45
Cash FlowN/A
Price / CashN/A
Book Value($0.68) per share
Price / Book-4.84
Profitability
EPS (Most Recent Fiscal Year)($0.53)
Net Income$-54,320,000.00
Net Margins-1,212.13%
Return on EquityN/A
Return on Assets-54.86%
Miscellaneous
Employees46
Outstanding Shares142,650,000
ZIOPHARM Oncology (NASDAQ:ZIOP) Frequently Asked Questions
What is ZIOPHARM Oncology's stock symbol?
ZIOPHARM Oncology trades on the NASDAQ under the ticker symbol "ZIOP."
How were ZIOPHARM Oncology's earnings last quarter?
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) issued its quarterly earnings results on Thursday, May, 10th. The biotechnology company reported ($0.15) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.13) by $0.02. The biotechnology company had revenue of $0.15 million for the quarter, compared to analyst estimates of $1.55 million. View ZIOPHARM Oncology's Earnings History.
When is ZIOPHARM Oncology's next earnings date?
What price target have analysts set for ZIOP?
3 brokers have issued 1 year target prices for ZIOPHARM Oncology's stock. Their forecasts range from $5.50 to $5.50. On average, they anticipate ZIOPHARM Oncology's share price to reach $5.50 in the next twelve months. View Analyst Ratings for ZIOPHARM Oncology.
What are Wall Street analysts saying about ZIOPHARM Oncology stock?
Here are some recent quotes from research analysts about ZIOPHARM Oncology stock:
- 1. According to Zacks Investment Research, "ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. " (5/16/2018)
- 2. HC Wainwright analysts commented, "We note that the biopsy analysis from the tumors of patients with rGBM, presented at SNO 2017, showed that Ad-RTS-hIL-12 plus veledimex monotherapy led to upregulation of PD-1 and PD-L1 receptors, suggesting a potential synergy between IL-12 and anti-PD-1 agents. Together with the shift to combinations, management also intends to expand the Ad-RTS-hIL-12 program beyond recurrent glioblastoma (rGBM) to include additional oncologic indications, such as breast cancer and melanoma. We note that the company plans to present an update of the biopsy analysis from the patients with rGBM and advanced breast cancer treated with Ad- RTS-hIL-12 plus veledimex at ASCO on June 4, 2018." (5/14/2018)
Are investors shorting ZIOPHARM Oncology?
ZIOPHARM Oncology saw a increase in short interest in the month of May. As of May 31st, there was short interest totalling 34,248,675 shares, an increase of 1.0% from the May 15th total of 34,594,585 shares. Based on an average trading volume of 980,531 shares, the short-interest ratio is presently 34.9 days. Approximately 26.8% of the company's stock are short sold. View ZIOPHARM Oncology's Current Options Chain.
Who are some of ZIOPHARM Oncology's key competitors?
Some companies that are related to ZIOPHARM Oncology include Phibro Animal Health (PAHC), Corcept Therapeutics (CORT), AnaptysBio (ANAB), Aimmune Therapeutics (AIMT), Myokardia (MYOK), Mallinckrodt (MNK), Zogenix (ZGNX), Biohaven Pharmaceutical (BHVN), G1 Therapeutics (GTHX), TherapeuticsMD (TXMD), Pacira Pharmaceuticals (PCRX), PTC Therapeutics (PTCT), Myovant Sciences (MYOV), Cambrex (CBM) and ARMO Biosciences (ARMO).
Who are ZIOPHARM Oncology's key executives?
ZIOPHARM Oncology's management team includes the folowing people:
- Dr. Laurence James Neil Cooper Ph.D., M.D., Chief Exec. Officer (Age 53)
- Mr. Kevin G. Lafond, Sr. VP of Fin., CFO, Chief Accounting Officer, Treasurer & Corp. Controller (Age 62)
- Dr. Francois Lebel M.D., Chief Medical Officer and Exec. VP of R&D (Age 66)
- Dr. David M. Mauney M.D., Exec. VP, Chief Bus. Officer & Interim COO (Age 49)
- Ms. Lynn M. Ferrucci PHR, Sr. VP of HR, Facilities, IT & Admin.
Has ZIOPHARM Oncology been receiving favorable news coverage?
News stories about ZIOP stock have been trending somewhat positive recently, Accern reports. The research group rates the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. ZIOPHARM Oncology earned a media sentiment score of 0.24 on Accern's scale. They also gave press coverage about the biotechnology company an impact score of 47.95 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
Who are ZIOPHARM Oncology's major shareholders?
ZIOPHARM Oncology's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.92%), UBS Group AG (0.61%), Schwab Charles Investment Management Inc. (0.47%), Wells Fargo & Company MN (0.18%), Russell Investments Group Ltd. (0.16%) and Summit Trail Advisors LLC (0.09%). Company insiders that own ZIOPHARM Oncology stock include David M Md Mauney and Laurence James Neil Cooper. View Institutional Ownership Trends for ZIOPHARM Oncology.
Which major investors are selling ZIOPHARM Oncology stock?
Which major investors are buying ZIOPHARM Oncology stock?
ZIOP stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., UBS Group AG, Summit Trail Advisors LLC, Mackay Shields LLC, Private Advisor Group LLC, Wealthcare Advisory Partners LLC, Wells Fargo & Company MN and Schwab Charles Investment Management Inc.. Company insiders that have bought ZIOPHARM Oncology stock in the last two years include David M Md Mauney and Laurence James Neil Cooper. View Insider Buying and Selling for ZIOPHARM Oncology.
How do I buy shares of ZIOPHARM Oncology?
Shares of ZIOP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ZIOPHARM Oncology's stock price today?
One share of ZIOP stock can currently be purchased for approximately $3.29.
How big of a company is ZIOPHARM Oncology?
ZIOPHARM Oncology has a market capitalization of $485.02 million and generates $6.39 million in revenue each year. The biotechnology company earns $-54,320,000.00 in net income (profit) each year or ($0.53) on an earnings per share basis. ZIOPHARM Oncology employs 46 workers across the globe.
How can I contact ZIOPHARM Oncology?
ZIOPHARM Oncology's mailing address is ONE FIRST AVENUE PARRIS BUILDING 34 NAVY YARD PLAZA, BOSTON MA, 02129. The biotechnology company can be reached via phone at 617-259-1970 or via email at [email protected]
MarketBeat Community Rating for ZIOPHARM Oncology (ZIOP)
MarketBeat's community ratings are surveys of what our community members think about ZIOPHARM Oncology and other stocks. Vote "Outperform" if you believe ZIOP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZIOP will underperform the S&P 500 over the long term. You may vote once every thirty days.
